BioCentury | Jul 13, 2018
Financial News

Haitong leads Orig3n's series B

...Regenerative medicine company Orig3n Inc. (Boston, Mass.) said it had an initial close of a series B...
...an initial close of a series B round led by Haitong International. A spokesperson for Orig3n...
...and Clearing Ltd. (HKEX) (see "Stealth, AOBiome Propose Hong Kong Offerings" ). Orig3n Inc., Boston, Mass. Sandi Wong Orig3n Inc....
BioCentury | Jul 12, 2018
Financial News

Haitong leads Orig3n's series B

...Regenerative medicine company Orig3n Inc. (Boston, Mass.) said it had an initial close of a series B...
...said it had an initial close of a series B round led by Haitong International. Orig3n...
...a $12.5 million series A co-led by Hatteras Venture Partners and Syno Capital in 2015. Orig3n...
BioCentury | Dec 14, 2016
Translation in Brief

Superdonor squad

...its goal of banking cells from one million donors, induced pluripotent stem (iPS) cell provider Orig3n Inc....
...However, finding superdonors is challenging, as they are few and far between. Founded in 2014, Orig3n...
...disease foundation meetings to professional sporting events and technology conferences. Unlike other cell banking companies, Orig3n...
BioCentury | Sep 26, 2016
Regulation

Not so fast

FDA documents concerning the review of Exondys 51 eteplirsen to treat DMD show that the chorus keening that the approval opens the floodgates for companies to combine shoddy, underpowered studies with patient activism to gain...
BioCentury | Sep 26, 2016
Regulation

How much is enough?

FDA Commissioner Robert Califf boiled the myriad conflicts over whether to grant accelerated approval to Sarepta Therapeutics Inc .'s Exondys 51 eteplirsen down to one fundamental scientific dispute. It all comes down to a disagreement...
BioCentury | Sep 26, 2016
Regulation

Digging into dosing

Clinical and preclinical data from Sarepta Therapeutics Inc. give hope that higher dosing of Exondys 51 eteplirsen could result in substantially higher dystrophin production than seen in its clinical trials. Figuring out how much and...
BioCentury | May 12, 2016
Emerging Company Profile

Crowdsourcing cells

...its proprietary reprogramming technologies and a bank of cells derived from nearly one million people, Orig3n Inc....
...could get 10 vials of cells from different patients?" Smith declined to disclose details about Orig3n's...
...has identified. Companies and Institutions Mentioned Orig3n Inc., Boston, Mass. Sidebars Orig3n Inc., Corporate Profile BC Staff Orig3n Inc....
BioCentury | Feb 9, 2015
Financial News

Orig3n completes venture financing

Orig3n Inc. , Boston, Mass. Business: Gene/Cell therapy, Neurology Date completed: 2015-02-05 Type: Venture financing Raised: $3.1 million Investors: Hatteras Venture Partners; Harris & Harris Group; KTB; Mountain Group Capital WIR Staff Neurology...
Items per page:
1 - 8 of 8
BioCentury | Jul 13, 2018
Financial News

Haitong leads Orig3n's series B

...Regenerative medicine company Orig3n Inc. (Boston, Mass.) said it had an initial close of a series B...
...an initial close of a series B round led by Haitong International. A spokesperson for Orig3n...
...and Clearing Ltd. (HKEX) (see "Stealth, AOBiome Propose Hong Kong Offerings" ). Orig3n Inc., Boston, Mass. Sandi Wong Orig3n Inc....
BioCentury | Jul 12, 2018
Financial News

Haitong leads Orig3n's series B

...Regenerative medicine company Orig3n Inc. (Boston, Mass.) said it had an initial close of a series B...
...said it had an initial close of a series B round led by Haitong International. Orig3n...
...a $12.5 million series A co-led by Hatteras Venture Partners and Syno Capital in 2015. Orig3n...
BioCentury | Dec 14, 2016
Translation in Brief

Superdonor squad

...its goal of banking cells from one million donors, induced pluripotent stem (iPS) cell provider Orig3n Inc....
...However, finding superdonors is challenging, as they are few and far between. Founded in 2014, Orig3n...
...disease foundation meetings to professional sporting events and technology conferences. Unlike other cell banking companies, Orig3n...
BioCentury | Sep 26, 2016
Regulation

Not so fast

FDA documents concerning the review of Exondys 51 eteplirsen to treat DMD show that the chorus keening that the approval opens the floodgates for companies to combine shoddy, underpowered studies with patient activism to gain...
BioCentury | Sep 26, 2016
Regulation

How much is enough?

FDA Commissioner Robert Califf boiled the myriad conflicts over whether to grant accelerated approval to Sarepta Therapeutics Inc .'s Exondys 51 eteplirsen down to one fundamental scientific dispute. It all comes down to a disagreement...
BioCentury | Sep 26, 2016
Regulation

Digging into dosing

Clinical and preclinical data from Sarepta Therapeutics Inc. give hope that higher dosing of Exondys 51 eteplirsen could result in substantially higher dystrophin production than seen in its clinical trials. Figuring out how much and...
BioCentury | May 12, 2016
Emerging Company Profile

Crowdsourcing cells

...its proprietary reprogramming technologies and a bank of cells derived from nearly one million people, Orig3n Inc....
...could get 10 vials of cells from different patients?" Smith declined to disclose details about Orig3n's...
...has identified. Companies and Institutions Mentioned Orig3n Inc., Boston, Mass. Sidebars Orig3n Inc., Corporate Profile BC Staff Orig3n Inc....
BioCentury | Feb 9, 2015
Financial News

Orig3n completes venture financing

Orig3n Inc. , Boston, Mass. Business: Gene/Cell therapy, Neurology Date completed: 2015-02-05 Type: Venture financing Raised: $3.1 million Investors: Hatteras Venture Partners; Harris & Harris Group; KTB; Mountain Group Capital WIR Staff Neurology...
Items per page:
1 - 8 of 8